Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

VIRAL ENTRY

ACE2, the viral gateway

Cell 181, 894–904 (2020)

Cell 181, 281–292 (2020)

On the basis of sequence information and knowledge of the cellular entry route of other coronaviruses, the host protein angiotensin-converting enzyme 2 (ACE2) was a prime candidate for the binding partner of the SARS-CoV-2 spike protein to enable viral entry.

Credit: Radoslav Zilinsky / Moment / Getty

Walls et al. showed that this spike protein enables SARS-CoV-2 to infect ACE2-expressing cells in vitro, and described a novel enzymatic cleavage site in the SARS-CoV-2 spike protein, which the authors propose may diversify the virus’ tissue tropism. The crystal structure of the C-terminal domain of SARS-CoV-2 spike protein bound to human ACE2 generated by Wang et al. predicts that the SARS-CoV-2 spike protein binds its target with greater affinity than that of its relative, SARS-CoV.

The two studies support the development of therapeutic and immunological strategies that target the viral spike protein’s ACE2-binding domains, and ACE2 expression in human tissues may explain both pulmonary viral tropism and extrapulmonary viral tropism.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Thiago Carvalho.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Carvalho, T. ACE2, the viral gateway. Nat Med 26, 1807 (2020). https://doi.org/10.1038/s41591-020-01166-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-020-01166-9

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing